Patents by Inventor Matthew Ronsheim

Matthew Ronsheim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200222541
    Abstract: The present invention is directed to stable linaclotide compositions and methods of treating gastrointestinal disorders in patients in need thereof by providing the stable linaclotide compositions.
    Type: Application
    Filed: January 11, 2019
    Publication date: July 16, 2020
    Inventors: Ritesh Sanghvi, Matthew Miller, Andreas Grill, Yun Mo, Mohammad Mafruhul Bari, Matthew Ronsheim, Joseph Stainkamp
  • Publication number: 20200157057
    Abstract: The present invention relates to processes and intermediates useful in the preparation of biologically active molecules, especially in the synthesis of Respiratory Syncytial Virus (RSV) inhibitors.
    Type: Application
    Filed: November 14, 2019
    Publication date: May 21, 2020
    Inventors: Andrew Hague, Matthew Ronsheim
  • Patent number: 10501422
    Abstract: The present invention relates to processes and intermediates useful in the preparation of biologically active molecules, especially in the synthesis of Respiratory Syncytial Virus (RSV) inhibitors.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: December 10, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Andrew Hague, Matthew Ronsheim
  • Publication number: 20180016301
    Abstract: Embodiments disclosed herein provide compounds and methods for preparing Beta-Arrestin Effectors.
    Type: Application
    Filed: February 17, 2017
    Publication date: January 18, 2018
    Inventors: Nhut K. Diep, Yuriy Kalyan, Graham Lawton, Matthew Ronsheim, Shao Hong Zhou, Saibaba Racha
  • Publication number: 20170281774
    Abstract: The present invention is directed to stable linaclotide compositions and methods of treating gastrointestinal disorders in patients in need thereof by providing the stable linaclotide compositions.
    Type: Application
    Filed: March 17, 2017
    Publication date: October 5, 2017
    Inventors: Ritesh Sanghvi, Matthew Miller, Andreas Grill, Yun Mo, Mohammad Mafruhul Bari, Matthew Ronsheim, Joseph Stainkamp
  • Publication number: 20170283464
    Abstract: The present disclosure provides novel crystalline forms of a compound that acts as a ?-arrestin effector, processes for preparing novel crystalline and amorphous forms of a compound that acts as a ?-arrestin effector and uses thereof.
    Type: Application
    Filed: November 7, 2016
    Publication date: October 5, 2017
    Inventors: Ritesh Sanghvi, Gregory Alcorn, Graham Richard Lawton, Meiki Yu, Matthew Ronsheim, Jiaher Tian, Shao Hong Zhou, Yuriy B. Kalyan
  • Patent number: 9611293
    Abstract: Embodiments disclosed herein provide compounds and methods for preparing Beta-Arrestin Effectors.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: April 4, 2017
    Assignee: Trevena, Inc.
    Inventors: Nhut K. Diep, Yuriy Kalyan, Graham Lawton, Matthew Ronsheim, Shao Hong Zhou, Saibaba Racha
  • Patent number: 9518086
    Abstract: The present disclosure provides novel crystalline forms of a compound that acts as a ?-arrestin effector, processes for preparing novel crystalline and amorphous forms of a compound that acts as a ?-arrestin effector and uses thereof.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: December 13, 2016
    Assignee: Trevena, Inc.
    Inventors: Ritesh Sanghvi, Gregory Alcorn, Graham Richard Lawton, Meiki Yu, Matthew Ronsheim, Jiaher Tian, Shao Hong Zhou, Yuriy B. Kalyan
  • Publication number: 20160324968
    Abstract: The present invention is directed to stable linaclotide compositions and methods of treating gastrointestinal disorders in patients in need thereof by providing the stable linaclotide compositions.
    Type: Application
    Filed: March 11, 2016
    Publication date: November 10, 2016
    Inventors: Ritesh Sanghvi, Matthew Miller, Andreas Grill, Yun Mo, Mohammad Mafruhul Bari, Matthew Ronsheim, Joseph Stainkamp
  • Patent number: 9283261
    Abstract: The present invention is directed to stable linaclotide compositions and methods of treating gastrointestinal disorders in patients in need thereof by providing the stable linaclotide compositions.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: March 15, 2016
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Ritesh Sanghvi, Matthew Miller, Andreas Grill, Yun Mo, Mohammad Mafruhul Bari, Matthew Ronsheim, Joseph Stainkamp
  • Publication number: 20150329593
    Abstract: Embodiments disclosed herein provide compounds and methods for preparing Beta-Arrestin Effectors.
    Type: Application
    Filed: May 19, 2015
    Publication date: November 19, 2015
    Inventors: Nhut K. Diep, Yuriy Kalyan, Graham Lawton, Matthew Ronsheim, Shao Hong Zhou, Saibaba Racha
  • Publication number: 20150225461
    Abstract: The present disclosure provides novel crystalline forms of a compound that acts as a ?-arrestin effector, processes for preparing novel crystalline and amorphous forms of a compound that acts as a ?-arrestin effector and uses thereof
    Type: Application
    Filed: February 6, 2015
    Publication date: August 13, 2015
    Inventors: Ritesh Sanghvi, Gregory Alcorn, Graham Richard Lawton, Meiki Yu, Matthew Ronsheim, Jiaher Tian, Shao Hong Zhou, Yuriy B. Kalyan
  • Publication number: 20150005241
    Abstract: The present invention is directed to stable linaclotide compositions and methods of treating gastrointestinal disorders in patients in need thereof by providing the stable linaclotide compositions.
    Type: Application
    Filed: September 18, 2014
    Publication date: January 1, 2015
    Inventors: Ritesh Sanghvi, Matthew Miller, Andreas Grill, Yun Mo, Mohammad Mafruhul Bari, Matthew Ronsheim, Joseph Stainkamp
  • Publication number: 20140005395
    Abstract: The present teachings provide a compound of Formula (I-B): wherein R1-R10 are as described herein; a pharmaceutically acceptable salt of the compound, a geometric isomer of the compound, or a pharmaceutically acceptable salt of the geometric isomer. Also described are methods of preparing the same, as well as methods for preparing vilazodone using the same.
    Type: Application
    Filed: July 1, 2013
    Publication date: January 2, 2014
    Inventor: Matthew Ronsheim
  • Patent number: 8349836
    Abstract: The present invention relates to novel phthalazine derivatives and, more particularly, to phthalazine derivatives that are useful as protein kinase inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: January 8, 2013
    Inventors: Gian-Luca Araldi, Matthew Ronsheim, Melanie Ronsheim
  • Patent number: 8044041
    Abstract: The present invention relates to novel phthalazine derivatives and, more particularly, to phthalazine derivatives of formula (III) that are useful as protein kinase inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: October 25, 2011
    Assignee: Forest Laboratories Holdings Limited
    Inventors: Gian-Luca Araldi, Matthew Ronsheim, Melanie Ronsheim
  • Publication number: 20110237571
    Abstract: The present invention relates to novel phthalazine derivatives and, more particularly, to phthalazine derivatives that are useful as protein kinase inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Application
    Filed: June 1, 2011
    Publication date: September 29, 2011
    Inventors: Gian-Luca Araldi, Matthew Ronsheim, Melanie Ronsheim
  • Publication number: 20100240611
    Abstract: Methods for preparing an inhibitor of dipeptidyl peptidase IV, as well as formulations of such inhibitors of dipeptidyl peptidase IV that have a high degree of stability including under warm, humid storage conditions.
    Type: Application
    Filed: March 16, 2010
    Publication date: September 23, 2010
    Inventors: Matthew Ronsheim, Nhut Diep, Yuriy Kalyan, Graham Lawton, Peng Wang, Michael Ouellette
  • Publication number: 20100168080
    Abstract: The present invention relates to novel morpholine, oxazapane and piperidine derivatives that act as ligands for CC chemokine receptors, such as CCR1. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
    Type: Application
    Filed: December 16, 2009
    Publication date: July 1, 2010
    Inventors: Uttam KHAMRAI, Sumit Kumar Karak, Matthew Ronsheim, Ashis Kumar Saha
  • Publication number: 20100152160
    Abstract: The present invention relates to benzodioxane and benzoxazine derivatives that act as ligands for CC chemokine receptors, such as CCR1. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
    Type: Application
    Filed: December 11, 2009
    Publication date: June 17, 2010
    Inventors: Uttam KHAMRAI, Matthew Ronsheim, Sumit Kumar Karak